Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | The interplay between T-ALL cells & TECs and the role of TECs in disease progression

Swaminathan Iyer • 10 Jun 2023
EHA 2023
Acute Lymphoblastic Leukemia Rare Diseases

Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the interplay between tumor-associated endothelial cells (TECs) and T-cell acute lymphoblastic leukemia (T-ALL) cells, explaining how targeting TECs might also help target T-ALL cells. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE

More from Swaminathan Iyer

3:17
PET imaging to predict treatment outcomes: follow-up from the ECHELON-2 trial
Swaminathan Iyer • 11 Dec 2023
2:39
The significance of CD30 in the response to brentuximab vedotin for patients with T-cell lymphoma
Swaminathan Iyer • 11 Dec 2023
5:32
A machine learning model to analyze histopathological tissue in DLBCL
Swaminathan Iyer • 11 Dec 2023
2:57
Lacutamab, an anti-KIR3DL2 monoclonal antibody, in the treatment of R/R PTCL
Swaminathan Iyer • 11 Dec 2023

Related Videos

8:40
Investigating PP2A-based therapeutic strategies for KMT2A-rearranged acute leukemia
Maria Teresa Esposito • 25 Apr 2024
1:46
Updated analyses from the PATHFINDER trial: avapritinib therapy in advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:32
Preventative therapeutic phlebotomies for patients with EPP
Rita Beier • 15 Apr 2024
1:57
TBI prior to alloSCT in patients with ALL: the FORUM trials
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals